SuperworthBristol-Myers Squibb profit margin BMY
Gross, operating and net profit as a share of revenue over the last twelve months, from 2009.
- Net margin, 12 months
- 18.9%
- Operating margin, 12 months
- 23.8%
- Net margin on a year earlier
- +8.3 pts
- Peer median
- 9.1%
Over the twelve months to Jun 30, 2026, Bristol-Myers Squibb kept 18.9% of its revenue as net profit, with an operating margin of 23.8% and a gross margin of 70.2%.
Five years earlier its net margin was −11.4%.
The median for 9 large drugmakers of a similar size is 9.1%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 14.6% | 20.8% | 71.1% |
| FY2024 | −18.5% | −15.5% | 71.1% |
| FY2023 | 17.8% | 16.2% | 76.2% |
| FY2022 | 13.7% | 18.0% | 78.0% |
| FY2021 | 15.1% | 15.9% | 78.6% |
| FY2020 | −21.2% | −21.6% | 72.3% |
| FY2019 | 13.2% | 22.6% | 69.1% |
| FY2018 | 21.8% | 22.7% | 71.3% |
| FY2017 | 4.8% | 16.6% | 70.7% |
| FY2016 | 22.9% | 23.8% | 74.5% |
| FY2015 | 9.5% | 11.4% | 76.4% |
| FY2014 | 12.6% | 16.3% | 75.2% |
| FY2013 | 15.6% | 18.9% | 71.8% |
| FY2012 | 11.1% | 12.8% | 73.8% |
| FY2011 | 17.5% | 30.7% | 73.6% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | 18.9% | +8.3 pts | 23.8% | |
| Q1 FY26 | 15.0% | +3.6 pts | 20.6% | |
| Q4 FY25 | 14.6% | +33.2 pts | 20.8% | |
| Q3 FY25 | 12.6% | +27.9 pts | 18.9% | |
| Q2 FY25 | 10.6% | +24.6 pts | 16.7% | |
| Q1 FY25 | 11.4% | +24.9 pts | 15.2% | |
| Q4 FY24 | −18.5% | −36.4 pts | −15.5% | |
| Q3 FY24 | −15.3% | −33.7 pts | −14.0% | |
| Q2 FY24 | −14.1% | −31.7 pts | −14.4% | |
| Q1 FY24 | −13.5% | −29.4 pts | −14.3% | |
| Q4 FY23 | 17.8% | +4.1 pts | 16.2% | |
| Q3 FY23 | 18.4% | +4.2 pts | 17.0% |
Against its peers
Companies in Drug Manufacturers - General nearest Bristol-Myers Squibb's size, closest first, today.
| Company | Profit margin |
|---|---|
| BMYBristol-Myers Squibb | 18.9% |
| PFEPfizer | 6.8% |
| GILDGilead Sciences | −10.6% |
| AMGNAmgen | 23.0% |
| MRKMerck | 4.8% |
| BIIBBiogen | 8.3% |
| ABBVAbbVie | 9.8% |
| JNJJohnson & Johnson | n/m |
| JAZZJazz Pharmaceuticals | 20.4% |
| LLYEli Lilly and | 33.5% |
| Peer median | 9.1% |
Where Bristol-Myers Squibb ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Bristol-Myers Squibb
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.